40 related articles for article (PubMed ID: 38622323)
1. Molecular subtypes of high-grade serous ovarian cancer across racial groups and gene expression platforms.
Davidson NR; Barnard ME; Hippen AA; Campbell A; Johnson CE; Way GP; Dalley BK; Berchuck A; Salas LA; Peres LC; Marks JR; Schildkraut JM; Greene CS; Doherty JA
Cancer Epidemiol Biomarkers Prev; 2024 May; ():. PubMed ID: 38780898
[TBL] [Abstract][Full Text] [Related]
2. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
3. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.
Bhattacharya R; Ghosh A; Mukhopadhyay S
Mol Biol Rep; 2023 Nov; 50(11):9511-9519. PubMed ID: 37737967
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the prognostic potential of histopathological subtyping in high-grade serous ovarian carcinoma.
Zelisse HS; Hwan RA; van de Vijver MJ; Dijk F; Mom CH; Hooijer GKJ; van Gent MDJM; Snijders MLH
Virchows Arch; 2024 Apr; ():. PubMed ID: 38622323
[TBL] [Abstract][Full Text] [Related]
5. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
[TBL] [Abstract][Full Text] [Related]
6. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
[TBL] [Abstract][Full Text] [Related]
7. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
8. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
9. Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging.
Miyagawa C; Nakai H; Otani T; Murakami R; Takamura S; Takaya H; Murakami K; Mandai M; Matsumura N
J Gynecol Oncol; 2023 Jul; 34(4):e47. PubMed ID: 36807749
[TBL] [Abstract][Full Text] [Related]
10. Deep learning-based histotype diagnosis of ovarian carcinoma whole-slide pathology images.
Farahani H; Boschman J; Farnell D; Darbandsari A; Zhang A; Ahmadvand P; Jones SJM; Huntsman D; Köbel M; Gilks CB; Singh N; Bashashati A
Mod Pathol; 2022 Dec; 35(12):1983-1990. PubMed ID: 36065012
[TBL] [Abstract][Full Text] [Related]
11. Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach.
Khashaba M; Fawzy M; Abdel-Aziz A; Eladawei G; Nagib R
J Egypt Natl Canc Inst; 2022 Feb; 34(1):6. PubMed ID: 35138498
[TBL] [Abstract][Full Text] [Related]
12. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.
Berek JS; Renz M; Kehoe S; Kumar L; Friedlander M
Int J Gynaecol Obstet; 2021 Oct; 155 Suppl 1(Suppl 1):61-85. PubMed ID: 34669199
[TBL] [Abstract][Full Text] [Related]
13. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.
Kos Z; Roblin E; Kim RS; Michiels S; Gallas BD; Chen W; van de Vijver KK; Goel S; Adams S; Demaria S; Viale G; Nielsen TO; Badve SS; Symmans WF; Sotiriou C; Rimm DL; Hewitt S; Denkert C; Loibl S; Luen SJ; Bartlett JMS; Savas P; Pruneri G; Dillon DA; Cheang MCU; Tutt A; Hall JA; Kok M; Horlings HM; Madabhushi A; van der Laak J; Ciompi F; Laenkholm AV; Bellolio E; Gruosso T; Fox SB; Araya JC; Floris G; Hudeček J; Voorwerk L; Beck AH; Kerner J; Larsimont D; Declercq S; Van den Eynden G; Pusztai L; Ehinger A; Yang W; AbdulJabbar K; Yuan Y; Singh R; Hiley C; Bakir MA; Lazar AJ; Naber S; Wienert S; Castillo M; Curigliano G; Dieci MV; André F; Swanton C; Reis-Filho J; Sparano J; Balslev E; Chen IC; Stovgaard EIS; Pogue-Geile K; Blenman KRM; Penault-Llorca F; Schnitt S; Lakhani SR; Vincent-Salomon A; Rojo F; Braybrooke JP; Hanna MG; Soler-Monsó MT; Bethmann D; Castaneda CA; Willard-Gallo K; Sharma A; Lien HC; Fineberg S; Thagaard J; Comerma L; Gonzalez-Ericsson P; Brogi E; Loi S; Saltz J; Klaushen F; Cooper L; Amgad M; Moore DA; Salgado R;
NPJ Breast Cancer; 2020; 6():17. PubMed ID: 32411819
[TBL] [Abstract][Full Text] [Related]
14. Epithelial ovarian cancer.
Lheureux S; Gourley C; Vergote I; Oza AM
Lancet; 2019 Mar; 393(10177):1240-1253. PubMed ID: 30910306
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
